Adverse reactions in the phase 3 clinical trial

Frequencya of important treatment-emergent adverse reactions

magnify

PERCENTAGE OF PATIENTS

  • Bone Marrow
  • Hypersensitivity reactionc
  • Cardiovascular
  • Abnormal ECG
  • Respiratory
  • Sensory neuropathy
  • Myalgia/Arthralgia
  • Asthenia
  • Fluid Retention/Edema
  • Gastrointestinal
  • Alopecia
  • Hepatic(Patients with normal baseline)
  • Injection site reaction
ECG=electrocardiogram.
AST=aspartate aminotransferase.
SGOT=serum glutamic-oxaloacetic transaminase.
aBased on worst grade by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 2.
bPaclitaxel injection patients received premedication.
cIncludes treatment-related events related to hypersensitivity (eg, flushing, dyspnea, chest pain, hypotension) that began on day of dosing.
dSevere events are defined as at least Grade 3 toxicity.

Adverse reactions in the phase 3 clinical trial

Frequencya of important treatment-emergent adverse reactions

Percentage of Patients

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.